| dbo:abstract |
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid-Cap segment on Nasdaq Stockholm with the stock ticker WTX. Wilson Therapeutics' lead product, Decuprate, is the proprietary bis-choline salt of tetrathiomolybdate. Decuprate is initially being developed as a novel treatment for Wilson's disease, a rare genetic disease that affects approximately 1 in 30,000, causing copper overload in the liver, brain and other tissues and resulting in organ damage and dysfunction. Decuprate has been granted orphan drug designation for the treatment of Wilson's disease in both Europe and the United States. Wilson Therapeutics presented during the 10th Kempen & Co Life Sciences Conference 2017 and showed the world the result with the drug Decuprate. The company also presented during the international investmentconference Bioequity Europe in Paris, France, on May 23, 2017, and showed some promising result. (en) |
| dbo:foundingYear |
2012-01-01 (xsd:gYear) |
| dbo:product |
dbr:Decuprate |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Wilson_Therapeutics_Company_Logo.png?width=300 |
| dbo:wikiPageExternalLink |
http://www.wilsontherapeutics.com |
| dbo:wikiPageID |
43152107 (xsd:integer) |
| dbo:wikiPageLength |
9550 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1110611057 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbc:Pharmaceutical_companies_of_Sweden dbc:Pharmaceutical_companies_established_in_2012 dbr:Genetic_disorder dbr:Orphan_drug dbr:Stockholm dbr:Decuprate dbc:2018_mergers_and_acquisitions dbc:Companies_based_in_Stockholm dbr:Wilson's_disease dbr:HealthCap dbr:Bis-choline_tetrathiomolybdate dbc:Orphan_drug_companies dbc:Swedish_companies_established_in_2012 dbr:Sweden dbr:Oncology dbr:Nasdaq_Stockholm |
| dbp:foundation |
2012 (xsd:integer) |
| dbp:homepage |
http://www.wilsontherapeutics.com |
| dbp:industry |
Pharmaceutical industry (en) |
| dbp:locationCity |
Stockholm (en) |
| dbp:locationCountry |
Sweden (en) |
| dbp:logo |
Wilson Therapeutics Company Logo.png (en) |
| dbp:name |
Wilson Therapeutics AB (en) |
| dbp:parent |
Alexion Pharmaceuticals (en) |
| dbp:products |
dbr:Decuprate |
| dbp:tradedAs |
OMX: WTX (en) |
| dbp:type |
Public company (en) |
| dbp:wikiPageUsesTemplate |
dbt:Citation_needed dbt:Cleanup_bare_URLs dbt:Infobox_company dbt:Reflist |
| dcterms:subject |
dbc:Pharmaceutical_companies_of_Sweden dbc:Pharmaceutical_companies_established_in_2012 dbc:2018_mergers_and_acquisitions dbc:Companies_based_in_Stockholm dbc:Orphan_drug_companies dbc:Swedish_companies_established_in_2012 |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment |
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid-Cap segment on Nasdaq Stockholm with the stock ticker WTX. (en) |
| rdfs:label |
Wilson Therapeutics (en) |
| owl:sameAs |
freebase:Wilson Therapeutics yago-res:Wilson Therapeutics wikidata:Wilson Therapeutics https://global.dbpedia.org/id/mXfV |
| skos:closeMatch |
http://www.grid.ac/institutes/grid.476835.b |
| prov:wasDerivedFrom |
wikipedia-en:Wilson_Therapeutics?oldid=1110611057&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Wilson_Therapeutics_Company_Logo.png |
| foaf:homepage |
http://www.wilsontherapeutics.com |
| foaf:isPrimaryTopicOf |
wikipedia-en:Wilson_Therapeutics |
| foaf:name |
Wilson Therapeutics AB (en) |
| is dbo:wikiPageWikiLink of |
dbr:Tiomolibdic_acid dbr:Wilson's_disease dbr:HealthCap dbr:Alexion_Pharmaceuticals |
| is foaf:primaryTopic of |
wikipedia-en:Wilson_Therapeutics |
